Rispoval IBR-Marker Live

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)

Aktīvā sastāvdaļa:

Infectious bovine rhinotraceitis virus

Pieejams no:

Zoetis UK Limited

ATĶ kods:

QI02AD01

SNN (starptautisko nepatentēto nosaukumu):

Infectious bovine rhinotraceitis virus

Zāļu forma:

Powder and solvent for solution for injection

Receptes veids:

POM-V - Prescription Only Medicine – Veterinarian

Ārstniecības grupa:

Cattle

Ārstniecības joma:

Live Viral Vaccine

Autorizācija statuss:

Authorized

Autorizācija datums:

1999-02-10

Produkta apraksts

Revised: November 2019
AN: 01038/2019
Page 1 of 8
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rispoval IBR-Marker Live
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Composition for 2 ml dose:
ACTIVE SUBSTANCE:
_Freeze-dried pellet_
Bovine Herpes Virus type 1 (BoHV-1), strain Difivac (gE-negative),
modified live (attenuated) virus
min. 10
5.0
CCID
50
*
max. 10
7.0
CCID
50
*
EXCIPIENT(S):
_Diluent_
Water for injections
2 ml
* CCID50 = Cell culture infective dose 50%
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and diluent for suspension for injection.
Lyophilisate: Slightly coloured freeze-dried pellet.
Diluent: Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of cattle against Infectious Bovine
Rhinotracheitis (IBR), to reduce
virus shedding and clinical signs including, in female cattle,
abortions associated with
BoHV-1 infection. A reduction of abortion associated with BoHV-1
infections has been
demonstrated during the second trimester of gestation upon challenge
28 days after
vaccination. Vaccinated cattle can be differentiated from field virus
infected animals due to
the marker deletion, unless the cattle were previously vaccinated with
a conventional
vaccine or infected with field virus.
Revised: November 2019
AN: 01038/2019
Page 2 of 8
_Onset of immunity_:
7 days after a single dose via intranasal administration or 21 days
after a single dose via
intramuscular administration as demonstrated in seronegative calves.
_Duration of immunity following vaccination before 3 months of age_:
After intranasal vaccination of calves aged 2 weeks or older without
maternally derived
antibodies, immunity lasts until at least 3 months of age, when the
animals should be
revaccinated via intramuscular injection.
A proportion of young calves may have maternally derived antibodies to
BoHV-1, which
may affect the immune response to vaccination. Conseque